drugset
drugset / Trial / NCT04470037

Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder

NCT04470037 ↗

Phase 2 Completed 61 enrolled China Medical University Hospital Ministry of Science and Technology, Taiwan · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading neurodegenerative disorders. Considering the fact that aged population is rapidly growing, it has become a critical issue to find more effective medications for these two disorders. The aim of this project is to examine the effectiveness and safety of DAAOI-P treatment for PD with dementia.

Timeline

Start
2016-04
Primary completion
2024-12
Completion
2025-09

Drugs

EvaluationDrugModalityDoseRoute
Subject DAAOI-P Unknown — —

Indications

Parkinson disease